News

Zoledronic Acid Shrinks Bone Marrow Lesions

Publish date: June 1, 2011
PDF Download

 

From the Annual European Congress of Rheumatology

MRI knee scans from two patients taken before (left) and 6 months after treatment with zoledronic acid show shrinkage of bone marrow lesions.

Source Courtesy Dr. Graeme Jones

Pages

Recommended Reading

Women on Denosumab Maintain Bone Benefits After 5 Years
MDedge Endocrinology
Atypical Fracture Risk Low for Bisphosphonates
MDedge Endocrinology
Denosumab's Bone Benefits Persist at 5 Years of Therapy
MDedge Endocrinology
New Guidance Aids Osteoporosis Screening
MDedge Endocrinology
Denosumab Gains New Indication, for Bone Metastases
MDedge Endocrinology
Local Corticosteroids Slowed RA Hand Bone Loss
MDedge Endocrinology
Nitroglycerin Ointment Strengthened Bone
MDedge Endocrinology
Zoledronic Acid Cuts Fractures at All Risk Levels
MDedge Endocrinology
Atypical Fractures Rare With Bisphosphonates
MDedge Endocrinology
Denosumab Curbs Fractures Equally at All Risk Levels
MDedge Endocrinology